| 14 0 (0%) | 03-06 09:30 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.35 | 1-year : | 19.09 |
| Resists | First : | 14 | Second : | 16.35 |
| Pivot price | 13.97  |
|||
| Supports | First : | 13.93 | Second : | 13.89 |
| MAs | MA(5) : | 13.99 |
MA(20) : | 13.96 |
| MA(100) : | 10.46 |
MA(250) : | 5.46 |
|
| MACD | MACD : | 0.2  |
Signal : | 0.3 |
| %K %D | K(14,3) : | 100 | D(3) : | 97.3 |
| RSI | RSI(14): 72.6 | |||
| 52-week | High : | 25 | Low : | 0.78 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ VTYX ] has closed below upper band by 12.7%. Bollinger Bands are 97.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 26 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 14.02 - 14.09 | 14.09 - 14.15 |
| Low: | 13.83 - 13.91 | 13.91 - 13.97 |
| Close: | 13.89 - 14.01 | 14.01 - 14.11 |
Ventyx Biosciences, Inc. is a biopharmaceutical company in the clinical development phase, specializing in the creation of small molecule therapeutics for inflammatory and autoimmune disorders. The company's primary investigational drug, VTX958, a tyrosine kinase type 2 (TYK2) inhibitor, is currently undergoing Phase I clinical trials. This compound aims to address a range of immune-mediated conditions, including psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. Among its pipeline assets is VTX002, an oral sphingosine 1 phosphate receptor 1 (S1P1) modulator, which has advanced to Phase II clinical studies for the treatment of ulcerative colitis. Additionally, VTX2735, a peripherally targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor, is in Phase I development, intended to combat systemic inflammatory diseases affecting cardiovascular, hepatic, renal, and rheumatologic systems. Furthermore, Ventyx is engaged in the development of CNS-penetrant NLRP3 inhibitors, with the objective of providing therapies for neurological ailments such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis. Founded in 2018, Ventyx Biosciences, Inc. is headquartered in Encinitas, California.
Mon, 01 Jun 2026
Ventyx Biosciences stock surges after Eli Lilly acquisition talks By Investing.com - Investing.com Nigeria
Thu, 09 Apr 2026
Ventyx Biosciences Inc (NASDAQ: VTYX) Stock Price, News & Analysis - Kalkine
Wed, 04 Mar 2026
Ventyx Biosciences completes $1.2 billion acquisition by Eli Lilly, delists from Nasdaq - Investing.com
Mon, 23 Feb 2026
Ventyx Biosciences agrees to $14.00 cash per share merger with Eli Lilly; HSR waiting period cleared - TradingView
Sun, 25 Jan 2026
Assessing Ventyx Biosciences (VTYX) Valuation After Sharp Share Price Momentum And A High P/B Multiple - Yahoo Finance
Mon, 12 Jan 2026
How This Newcomer Is Taking On Eli Lilly's $1.2 Billion Buyout - Investor's Business Daily
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 72 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 4.2 (%) |
| Held by Institutions | 84.5 (%) |
| Shares Short | 4,480 (K) |
| Shares Short P.Month | 4,550 (K) |
| EPS | -1.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.68 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.5 % |
| Return on Equity (ttm) | -45.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.63 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -88 (M) |
| Levered Free Cash Flow | -47 (M) |
| PE Ratio | -9.4 |
| PEG Ratio | 0 |
| Price to Book value | 5.22 |
| Price to Sales | 0 |
| Price to Cash Flow | -11.45 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|